These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 24641261)

  • 1. Bucillamine-induced pemphigus vulgaris.
    Yanagishita T; Tamada Y; Watanabe D
    J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1242-3. PubMed ID: 24641261
    [No Abstract]   [Full Text] [Related]  

  • 2. [A case of rheumatoid arthritis developing pemphigus-like skin lesion during treatment with bucillamine].
    Amasaki Y; Sagawa A; Atsumi T; Jodo S; Nakabayashi T; Watanabe I; Mukai M; Fujisaku A; Nakagawa S; Kobayashi H
    Ryumachi; 1991 Oct; 31(5):528-34; discussion 531-3. PubMed ID: 1837388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-induced pemphigus foliaceus with features of pemphigus vulgaris.
    Ogata K; Nakajima H; Ikeda M; Yamamoto Y; Amagai M; Hashimoto T; Kodama H
    Br J Dermatol; 2001 Feb; 144(2):421-2. PubMed ID: 11251589
    [No Abstract]   [Full Text] [Related]  

  • 4. Bucillamine-induced pemphigus vulgaris in a patient with rheumatoid arthritis and polymyositis overlap syndrome.
    Hur JW; Lee CW; Yoo DH
    J Korean Med Sci; 2006 Jun; 21(3):585-7. PubMed ID: 16778412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcorneal pustular dermatosis-type IgA pemphigus induced by thiol drugs.
    Kishimoto K; Iwatsuki K; Akiba H; Motoki Y; Kaneko F
    Eur J Dermatol; 2001; 11(1):41-4. PubMed ID: 11174137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug eruption due to bucillamine.
    Kimura M; Kawada A
    Contact Dermatitis; 1998 Aug; 39(2):98-9. PubMed ID: 9746202
    [No Abstract]   [Full Text] [Related]  

  • 7. Pemphigus foliaceus induced by bucillamine.
    Fujita H; Iguchi M; Watanabe R; Asahina A
    Eur J Dermatol; 2007; 17(1):98-9. PubMed ID: 17324844
    [No Abstract]   [Full Text] [Related]  

  • 8. [A case of pulmonary infiltration with eosinophilia (PIE) syndrome induced by bucillamine treatment of rheumatoid arthritis].
    Kishimoto N; Fujii K
    Nihon Kokyuki Gakkai Zasshi; 2002 Apr; 40(4):321-5. PubMed ID: 12096503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bucillamine-induced toxic epidermal necrolysis and fixed drug eruption.
    Izumi A; Katsumi S; Kobayashi N; Niizeki H; Asada H; Miyagawa S
    J Dermatol; 2005 May; 32(5):397-401. PubMed ID: 16043905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bucillamine-associated membranous nephropathy in a patient with rheumatoid arthritis].
    Kawano M; Nomura H; Iwainaka Y; Nakashima A; Koni I; Tofuku Y; Takeda R
    Nihon Jinzo Gakkai Shi; 1990 Jul; 32(7):817-21. PubMed ID: 2273598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rheumatoid arthritis exacerbation by G-CSF treatment for bucillamine-induced agranulocytosis.
    Nakashima H; Kawabe K; Ohtsuka T; Hayashida K; Horiuchi T; Nagasawa K; Niho Y
    Clin Exp Rheumatol; 1995; 13(5):677-9. PubMed ID: 8575155
    [No Abstract]   [Full Text] [Related]  

  • 12. [A case of rheumatoid arthritis associated with agranulocytosis during bucillamine treatment].
    Negishi M; Yamazaki J; Hosaka M; Iwabuchi H; Matsuda A; Kanemitsu H; Hiramatsu K; Kaga S; Hashimoto M; Kasama T
    Ryumachi; 1994 Jun; 34(3):651-5. PubMed ID: 8052932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunopharmacological evaluation of bucillamine in rheumatoid arthritis.
    Matsuno H; Kitano T; Matsushita I; Tsuji H; Ochiai H
    Drugs Exp Clin Res; 1993; 19(5):205-11. PubMed ID: 8174492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of clinical effects of bucillamine between additive combination and single administration study in rheumatoid arthritis.
    Nobunaga M; Yasuda M
    Agents Actions Suppl; 1993; 44():105-9. PubMed ID: 8372720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A case of drug-induced interstitial pneumonitis in rheumatoid arthritis treated with bucillamine].
    Matsushima H; Takayanagi N; Sakamoto T; Motegi M; Ubukata M; Yanagisawa T; Sugita Y; Kanazawa M; Kawabata Y
    Nihon Kokyuki Gakkai Zasshi; 2001 Jan; 39(1):55-9. PubMed ID: 11296388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Yellow nails under bucillamine therapy for rheumatoid arthritis: a report of two cases.
    Yamamoto T; Yokozeki H
    Rheumatol Int; 2007 Apr; 27(6):603-4. PubMed ID: 17103174
    [No Abstract]   [Full Text] [Related]  

  • 17. [Lung injury associated with bucillamine therapy].
    Negishi M; Kaga S; Kasama T; Hashimoto M; Fukushima T; Yamagata N; Tabata M; Kobayashi K; Ide H; Takahashi T
    Ryumachi; 1992 Apr; 32(2):135-9. PubMed ID: 1595005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diclofenac: a new trigger of pemphigus vulgaris?
    Matz H; Bialy-Golan A; Brenner S
    Dermatology; 1997; 195(1):48-9. PubMed ID: 9267738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Yellow nail induced by bucillamine.
    Ishizaki C; Sueki H; Kohsokabe S; Nishida H
    Int J Dermatol; 1995 Jul; 34(7):493-4. PubMed ID: 7591416
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinicopathological findings of bucillamine-induced nephrotic syndrome in patients with rheumatoid arthritis.
    Yoshida A; Morozumi K; Suganuma T; Sugito K; Ikeda M; Oikawa T; Fujinami T; Takeda A; Koyama K
    Am J Nephrol; 1991; 11(4):284-8. PubMed ID: 1799186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.